Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.
Glucagon-like peptide-1 (GLP-1) and CCK-33 were intravenously infused alone or in combination into normal weight men for 60 min before they were served a lunch of ham sandwiches, chocolate mousse, and orange juice. Infusion of GLP-1 (dose: 0.9 pmol x kg(-1) x min(-1)) or CCK-33 (dose: 0.2 pmol x kg(-1) x min(-1)) each reduced calorie intake of the test meal. However, simultaneous infusion of these peptide doses reduced calorie intake less than the sum of the peptides' individual effects. Infusions of the same doses of GLP-1 plus CCK-33 had neither individual nor interactive effects on meal size or calorie consumption. The combination of GLP-1 plus CCK-33 induced, however, a significant reduction in hunger feelings in the premeal period (P = 0.036 vs. all other treatments). In summary, intravenous infusion of near physiological doses of CCK-33 and GLP-1 produced specific inhibitions of hunger feeling in men; the simultaneous infusion resulted in an infra-additive reduction in calorie consumption, rejecting thereby the hypothesis that the two peptides exert a positive synergistic effect on food intake compared with the effects observed with infusion of individual peptides. In conclusion, CCK and GLP-1 are meal-related satiety signals that are released from the gastrointestinal tract during food intake.
Gutzwiller
Jean-Pierre
JP
Clinical Research Center and Department of Research, University Hospital, CH-4031 Basel, Switzerland.
Degen
Lukas
L
Matzinger
Daniel
D
Prestin
Sven
S
Beglinger
Christoph
C
D000328:Adult; D001066:Appetite / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis; D002766:Cholecystokinin / Q000008:administration & dosage* / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects*; D005934:Glucagon / Q000008:administration & dosage*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D011498:Protein Precursors / Q000008:administration & dosage*; D012528:Satiety Response
D001786:Blood Glucose; D004338:Drug Combinations; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D002766:Cholecystokinin